24/08/2026
๐ฆ ๐ ๐ฒ๐ถ๐ฏ๐ผ๐ด๐ฟ๐ฎ๐ฝ๐ต๐. ๐๐ฒ๐๐ผ๐ป๐ฑ ๐๐ต๐ฒ ๐ด๐น๐ฎ๐ป๐ฑ๐.
With TFOS DEWS III, the message is clear:
๐๐๐ข ๐๐๐โ๐ก ๐ก๐๐๐๐ก ๐๐๐ฆ ๐๐ฆ๐ ๐๐๐๐๐๐ก๐๐ฃ๐๐๐ฆ ๐๐ ๐ฆ๐๐ข ๐๐๐โ๐ก ๐ข๐๐๐๐๐ ๐ก๐๐๐ ๐๐ก๐ ๐๐๐ข๐ ๐.
Meibomian Gland Dysfunction (MGD) lies at the core of Dry Eye Disease, yet it cannot be fully assessed without imaging.
๐ฑAnd today, with intensive screen use (work, smartphones, gaming) and reduced blink quality, gland dysfunction is appearing earlier and progressing faster.
MGD is now frequently observed even in younger patients.
This makes early and objective detection through meibography not just useful โ but essential.
Because one principle stands out:
The earlier MGD is diagnosed and treated, the more we prevent progression to severe stages where gland loss becomes irreversible.
Meibography (upper & lower lids) enables:
๐งEarly detection of gland loss and altered functionality
๐งObjective, reproducible assessment of MGD
๐งMechanismโbased treatment decisions before itโs too late
To meet TFOS DEWS III report expectations, diagnostics must be objective, nonโinvasive, and mechanismโdriven.
โถ๏ธ This is exactly what C.DIAGยฎ brings: fast, highโcontrast transillumination meibography for clear visualization of gland structure, supporting earlier intervention and better longโterm outcomes.
Meibography is no longer optional.
Itโs becoming the standard of care across all patient profiles, even the youngest screenโheavy users.
